The U.S. Food and Drug Administration (FDA) revised the label for Metformin Hydrochloride, effective 2026-01-28, to include a new boxed warning. This warning, titled "WARNING: LACTIC ACIDOSIS," states that postmarketing cases of metformin-associated lactic acidosis have resulted in severe outcomes, including death, hypothermia, hypotension, and resistant bradyarrhythmias. The FDA further notes that the onset of metformin-associated lactic acidosis is often subtle, accomp.
What this means
The addition of a boxed warning to the Metformin Hydrochloride label emphasizes the critical importance for clinicians to be vigilant for signs and symptoms of lactic acidosis in patients. Healthcare providers should be aware that the onset of metformin-associated lactic acidosis is often subtle, accomp, making early recognition challenging. Given the severe and potentially fatal outcomes observed in postmarketing cases, including death, hypothermia, hypotension, and resistant bradyarrhythmias, it is crucial for prescribers to counsel patients on these risks and to consider appropriate monitoring strategies. This label change serves as a reminder of the serious nature of this adverse event associated with Metformin Hydrochloride therapy.
Source
The information regarding this label revision was obtained from the U.S. Food and Drug Administration (FDA) through its DailyMed database. The updated label for Metformin Hydrochloride, effective 2026-01-28, is documented on dailymed.nlm.nih.gov.